Meiji Pharmaceutical University · Unclassified

Research keywordsclinical pharmacokinetics・CYP3A phenotyping・OATP1B biomarkers・belimumab therapeutic monitoring・LC-MS/MS bioanalysis・chronic kidney disease pharmacology

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• The active metabolite hydroxyitraconazole has substantially higher in vivo free fraction and free concentrations compared to itraconazole. J Pharm Biomed Anal, 259, 116775 (2025)2025
• Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotyping. Clin Transl Sci, 17, e13768 (2024)2024
• Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review. Curr Ther Res Clin Exp, 100, 100738 (2024)2024
• Relationship of plasma 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid concentration with OATP1B activity in patients with chronic kidney disease. Clin Transl Sci, 17, e13731 (2024)2024

• がん治療関連心血管毒性の発現及び予後を予測する有用なバイオマーカーの開発
• 分子・細胞から集団レベルまでを包括したPFASの発がん性に対する分野横断的研究
• 慢性腎不全患者に肝代謝型薬物の用量調節は必要か？－CYP3A活性低下の要因探索
• 新規SLE抗体医薬品の治療効果最大化を目指した臨床薬理学研究

• Official profile